ArticleAsian biomedicine : research, reviews and news2026
Efficacy of GnRH-a in combination with dienogest therapy in endometriosis and its effects in recurrence and pregnancy status.
Article in Asian biomedicine : research, reviews and news, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endometriosis (EMT) is a common gynecologic and hormone-dependent disease that seriously affects patients' quality of life and currently faces certain challenges in clinical treatment. Objective: To observe the clinical efficacy of gonadotropin-releasing hormone agonists (GnRH-a) in combination with Dienogest treatment in EMT and its effects on recurrence and pregnancy. Methods: In a retrospective study, 254 patients with EMT from The First Affiliated Hospital, College of Medicine, Zhejiang University were selected between October 2020 and December 2021, and were divided into DT group (Dienogest treatment group) and GD group (GnRH-a combined with dienogest treatment group) according to the treatment modality, both groups were treated with Dienogest, and the GD group was additionally treated with GnRH-a. The primary assessment of both groups was clinical efficacy, recurrence rate and pregnancy (cumulative pregnancy rate, live birth rate, miscarriage rate, multiple pregnancy rate, and ectopic pregnancy rate). Secondary outcomes included the antibody indicator positive rate (anti-endometrial antibodies [AEmAb], anti-sperm antibodies [AsAb], and anti-zona pellucida antibodies [AZpAb]), sex hormone levels (luteinizing hormone [LH], follicle-stimulating hormone [FSH], and estradiol [E2]), serum inflammatory indicator levels (Interleukin-6 [IL-6], C-reactive protein [CRP], tumor necrosis factor-α [TNF-α]), visual analog scale (VAS) scores, and adverse reactions. Results: After treatment, all indicators improved in both groups ( Conclusion: The efficacy of GnRH-a combined with Dienogest in the treatment of EMT is remarkable, which can effectively reduce the inflammatory response, sex hormone levels, and recurrence rate, and markedly improve pregnancy, which is worth promoting its use in the clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.